Treatment

Telavancin (7.5–10 mg/kg q24–48h, based on CrCl) is a lipoglycopeptide antibiotic that is FDA-approved for treatment of HABP and VABP caused by S. aureus and for complicated skin/soft tissue infections. Telavancin is broadly active against gram-positive bacteria, including MRSA, VISA, heteroresistant VISA, daptomycin- and linezolid-resistant S. aureus, streptococci, vancomycin-sensitive enterococci, and some gram-positive anaerobes. The agent is not active against gram-negative bacteria, vancomycin-resistant S. aureus, and VRE.